MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-08-2023
Invitae Corporation Retained Earnings 2011-2026 | NVTA
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Invitae Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.83 B | -1.72 B | -1.36 B | -759 M | -517 M | -399 M | -275 M | -175 M | -85.2 M | -37.7 M | -12.8 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -12.8 M | -4.83 B | -925 M |
Quarterly Retained Earnings Invitae Corporation
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.17 B | -5.23 B | -5.02 B | -4.83 B | -4.73 B | -4.43 B | -1.9 B | -1.72 B | -1.52 B | -1.32 B | -1.45 B | -1.36 B | -1.36 B | -1.36 B | -1.36 B | -759 M | -759 M | -759 M | -759 M | -517 M | -517 M | -517 M | -517 M | -399 M | -399 M | -399 M | -399 M | -275 M | -275 M | -275 M | -275 M | -175 M | -175 M | -175 M | -175 M | -85.2 M | -85.2 M | -85.2 M | -85.2 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -85.2 M | -6.17 B | -1.35 B |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Brainsway Ltd.
BWAY
|
-77.3 M | $ 24.33 | 5.28 % | $ 99.4 M |  Israel |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M |  USA |
 |
Check-Cap Ltd.
CHEK
|
-170 M | - | - | $ 9.42 M | Israel |
 |
Burning Rock Biotech Limited
BNR
|
-2.23 B | $ 23.41 | 0.47 % | $ 252 M |  China |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
 |
Castle Biosciences
CSTL
|
-200 M | $ 39.7 | 0.92 % | $ 1.1 B | USA |
 |
Co-Diagnostics
CODX
|
4.6 M | $ 6.0 | -3.07 % | $ 176 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-607 M | - | -61.36 % | $ 2.46 M | USA |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
DexCom
DXCM
|
1.02 B | $ 70.68 | 4.87 % | $ 27.3 B | USA |
 |
BioNano Genomics
BNGO
|
-693 M | $ 1.58 | - | $ 2.01 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
 |
Guardant Health
GH
|
-2.58 B | $ 107.76 | -2.19 % | $ 13.2 B | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-150 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
 |
Illumina
ILMN
|
-1.24 B | $ 145.25 | 2.96 % | $ 23.1 B | USA |
 |
IQVIA Holdings
IQV
|
6.06 B | $ 241.11 | -0.55 % | $ 43.7 B | USA |
 |
CareDx, Inc
CDNA
|
-678 M | $ 20.41 | 19.15 % | $ 1.1 B | USA |
 |
Danaher Corporation
DHR
|
44.2 B | $ 238.83 | 0.2 % | $ 175 B | USA |
 |
Celcuity
CELC
|
-272 M | $ 104.34 | -2.95 % | $ 4.12 B | USA |
 |
DarioHealth Corp.
DRIO
|
-349 M | $ 11.97 | -1.56 % | $ 340 M | Israel |
 |
Anixa Biosciences
ANIX
|
-252 M | $ 3.19 | -5.62 % | $ 102 K | USA |
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | USA |
 |
Lantheus Holdings
LNTH
|
446 M | $ 67.28 | -0.41 % | $ 4.66 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-4.5 B | $ 102.23 | 0.11 % | $ 18.9 B | USA |
 |
Fulgent Genetics
FLGT
|
590 M | $ 28.16 | 1.11 % | $ 851 M | USA |
 |
Medpace Holdings
MEDP
|
8.17 M | $ 599.7 | 0.79 % | $ 18.6 B | USA |
 |
Aspira Women's Health
AWH
|
-499 M | - | -6.19 % | $ 10.5 M | USA |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | Israel |
 |
Myriad Genetics
MYGN
|
-757 M | $ 6.56 | -0.3 % | $ 594 M | USA |
 |
Charles River Laboratories International
CRL
|
1.81 B | $ 219.73 | -0.62 % | $ 11.3 B | USA |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | USA |
 |
National Research Corporation
NRC
|
-30.5 M | $ 20.3 | 2.94 % | $ 498 M | USA |
 |
Mettler-Toledo International
MTD
|
8.37 B | $ 1 486.95 | 0.1 % | $ 31.6 B |  Schweiz |
 |
Natera
NTRA
|
-1.94 B | $ 233.65 | -0.28 % | $ 23 B | USA |
 |
ENDRA Life Sciences
NDRA
|
-103 M | $ 4.51 | -3.01 % | $ 2.42 M | USA |
 |
Neogen Corporation
NEOG
|
-536 M | $ 9.33 | -3.01 % | $ 2.02 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.36 B | $ 175.05 | 0.34 % | $ 19.4 B | USA |
|
Biodesix
BDSX
|
-462 M | $ 8.2 | 50.18 % | $ 1.06 B | USA |
 |
Organovo Holdings
ONVO
|
-342 M | - | -2.3 % | $ 19.4 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.3 B | $ 249.91 | -0.75 % | $ 21 B | USA |
 |
ICON Public Limited Company
ICLR
|
2.72 B | $ 180.43 | -0.52 % | $ 14.9 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
5.33 B | $ 722.17 | 1.24 % | $ 59.6 B | USA |